文献速递血液净化与透析肾血管病与高血压

枸橼酸透析液意外促进血管钙化

Effect of Hemodialysis With Citrate on Vascular Calcification.
PubMed 文献 · Kidney Int Rep · 2026-05-25

交叉研究纳入28例已有乳腺动脉钙化的女性血液透析患者,分别使用含枸橼酸与不含枸橼酸透析液各1年,每6个月测量乳腺动脉钙化。含枸橼酸透析期间钙化进展显著更快(47 vs 9 mm/年,P=0.0005),79%受试者进展更明显;钙化人动脉中检出枸橼酸且与钙化程度相关(r=0.91),提示枸橼酸可能促进血管钙化而非抑制。

要点

  • 含枸橼酸透析液使透析后血浆枸橼酸升高超200%,但透析前钙、磷、枸橼酸无变化。
  • 含枸橼酸透析期间乳腺动脉钙化进展显著快于无枸橼酸透析(47 vs 9 mm/年,P=0.0005)。
  • 钙化人动脉中枸橼酸水平与钙化程度相关(r=0.91),接近骨中水平。

核心结论

  • 含枸橼酸透析液意外促进血管钙化,且不能由其他透析参数或矿物质代谢变化解释。
  • 枸橼酸存在于钙化人动脉中,其水平接近骨中报道的水平。
  • 该结果与枸橼酸促进生物矿化和骨形成的已知效应一致。

研究设计与样本

  • 交叉研究,28例慢性中心血液透析女性患者,均有预先存在的乳腺动脉钙化。
  • 分别使用含或不含枸橼酸透析液各1年,每6个月测量乳腺动脉钙化。
  • 另检测钙化人动脉中的枸橼酸含量。

主要发现

  • 含枸橼酸透析使透析后血浆枸橼酸升高超过200%,透析前枸橼酸、钙、磷无变化。
  • 含枸橼酸透析期间乳腺动脉钙化进展显著大于无枸橼酸透析(47,IQR 10-124 vs 9,IQR -4至34 mm/年,P=0.0005)。
  • 79%的受试者在含枸橼酸透析期间钙化进展更大。
  • 钙化人动脉中枸橼酸与钙化程度相关(r=0.91)。

临床怎么用

  • 对于已有血管钙化的血液透析女性患者,使用含枸橼酸透析液需警惕钙化进展加速。
  • 需进一步研究明确枸橼酸透析是否导致不良临床结局,以及其他枸橼酸治疗用途是否也有此效应。

局限性

  • 研究仅纳入女性患者,结果外推需谨慎。
  • 样本量较小(28例),需更大规模研究验证。
  • 未评估临床结局,仅以乳腺动脉钙化为替代指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Vascular calcification, specifically medial calcification, is prevalent in patients undergoing hemodialysis (HD) and leads to poor outcomes. Citrate is present in some HD solutions and could potentially inhibit vascular calcification. This was examined by comparing the progression of medial arterial calcification, as measured using mammography, in female patients with end-stage renal disease (ESRD) undergoing HD with and without citrate. METHODS: In a cross-over study, 28 female chronic in-center HD patients with preexisting breast arterial calcification (BAC) underwent HD using dialysate with or without citrate, each for 1 year with BAC measured at 6-month intervals. In addition, citrate was measured in calcified human arteries. RESULTS: HD with citrate increased post-HD plasma citrate over 200% with no changes in pre-HD levels of citrate, calcium (Ca), or phosphate. Progression of BAC was significantly greater during citrate HD (47, interquartile range [IQR]:10-124 vs. 9 , IQR: -4 to 34 mm/yr, P = 0.0005), with 79% of subjects having greater progression during citrate HD. Citrate was present in calcified human arteries and correlated with the degree of calcification (r = 0.91). CONCLUSION: HD with citrate unexpectedly promoted vascular calcification, which could not be explained by other dialysis parameters or changes in mineral metabolism. In addition, citrate was associated with vascular calcifications at levels approaching those reported in bone. The results are consistent with known effects of citrate to promote biomineralization and bone formation. Further studies are needed to determine whether this effect of citrate leads to adverse clinical outcomes in patients undergoing HD and occurs with other therapeutic uses of citrate.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. O'Neill WC, Navarrete J, Young M, et al. Effect of Hemodialysis With Citrate on Vascular Calcification. Kidney Int Rep. 2026. PMID: 42381770. doi:10.1016/j.ekir.2026.106621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。